Andrea Ladanyi
Affiliations: | Semmelweis Egyetem, Hungary |
Area:
Oncology, Cell BiologyGoogle:
"Andrea Ladanyi"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Baghy K, Ladányi A, Reszegi A, et al. (2023) Insights into the Tumor Microenvironment-Components, Functions and Therapeutics. International Journal of Molecular Sciences. 24 |
| Federspiel J, Greier MDC, Ladányi A, et al. (2023) p38 Mitogen-Activated Protein Kinase Inhibition of Mesenchymal Transdifferentiated Tumor Cells in Head and Neck Squamous Cell Carcinoma. Biomedicines. 11 |
| Ladányi A, Hegyi B, Balatoni T, et al. (2022) HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. Pathology Oncology Research : Por. 28: 1610297 |
| Küronya Z, Szőnyi MD, Nagyiványi K, et al. (2020) Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer. Pathology Oncology Research : Por |
| Ladányi A, Papp E, Mohos A, et al. (2020) Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma. Journal For Immunotherapy of Cancer. 8 |
| Dudas J, Ladanyi A, Ingruber J, et al. (2020) Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. Cells. 9 |
| Ladányi A, Tímár J. (2019) Immunologic and immunogenomic aspects of tumor progression. Seminars in Cancer Biology |
| Burián Z, Ladányi A, Barbai T, et al. (2019) Selective Inhibition of HIF1α Expression by ZnSO Has Antitumoral Effects in Human Melanoma. Pathology Oncology Research : Por |
| Ladányi A, Kapuvári B, Papp E, et al. (2018) Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. Head & Neck |
| Balatoni T, Ladányi A, Fröhlich G, et al. (2018) Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Pathology Oncology Research : Por |